HDPR1, a novel inhibitor of the WNT/β-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing
- 6 December 2004
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 24 (9), 1607-1614
- https://doi.org/10.1038/sj.onc.1208340
Abstract
Oncogenic activation of the WNT/β-catenin signaling pathway is common in hepatocellular carcinoma (HCC). Dishevelled (Dvl), a key activator of the pathway, inhibits the adenomatous polyposis coli complex, and this leads to the accumulation of β-catenin and promotes tumorigenesis. Recently, a novel inhibitor of Dishevelled, namely Dapper (Dpr), was isolated in Xenopus. To explore whether HDPR1, the human homologue of Dpr, has an anti-oncogenic role in hepatocarcinogenesis, we studied the expression of this gene in HCCs. We found that there were two alternatively spliced transcripts of HDPR1, designated as α and β forms, in human liver. Downregulation of the gene expression was observed in 31 (43%) of the 72 human HCC samples using the primer pair that amplified both transcripts. Furthermore, the HDPR1α was downregulated in 42 (58%) of 72 human HCCs and the downregulation significantly correlated with accumulation of β-catenin. Also, downregulation of HDPR1 by RNA interference in HLE cells led to cytoplasmic accumulation of β-catenin. Furthermore, a CpG island located at the promoter region and exon 1 of the HDPR1 gene was methylated in 22 (51%) of human HCCs. We showed that downregulation of HDPR1, in hepatoma cell lines, was associated with methylation of this CpG island using bisulfite sequencing and 5-aza-2′-deoxycytidine demethylation experiment. In addition to methylation-mediated downregulation of HDPR1, allelic loss (13–28% of informative cases) was detected using microsatellite markers flanking the HDPR1 locus. To conclude, downregulation of HDPR1 is common in HCCs, frequently involves hypermethylation of the promoter region, and allelic loss of the HDPR1 locus may also play a role.This publication has 27 references indexed in Scilit:
- Evaluation of Nuclear Factor-κB, Urokinase-Type Plasminogen Activator, and HBx and Their Clinicopathological Significance in Hepatocellular CarcinomaClinical Cancer Research, 2004
- PIN1 overexpression and β-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinomaOncogene, 2004
- c‐jun NH2‐terminal kinase pathway is involved in constitutive matrix metalloproteinase‐1 expression in a hepatocellular carcinoma‐derived cell lineInternational Journal of Cancer, 2004
- Beta‐catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E‐cadherin and accumulation of p53, but not with expression of conventional WNT‐1 target genesThe Journal of Pathology, 2003
- c-Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regenerationJournal of Hepatology, 2003
- Altered expression of E-cadherin in hepatocellular carcinoma: Correlations with genetic alterations, β-catenin expression, and clinical featuresJournal of Hepatology, 2002
- Mutational spectrum of β-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomasOncogene, 2002
- AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1Nature Genetics, 2000
- Difference in gene expression for matrix metalloproteinase-1 between early and advanced hepatocellular carcinomasJournal of Hepatology, 1997
- Expression of insulin-like growth factor II in hepatitis B, cirrhosis and hepatocellular carcinoma: Its relationship with hepatitis B virus antigen expressionJournal of Hepatology, 1994